INEGY 10 MG/10 MG TABLETS

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

EZETIMIBE 10 MG; SIMVASTATIN 10 MG

Available from:

MERCK SHARP & DOHME ISRAEL LTD

ATC code:

C10AA01

Pharmaceutical form:

TABLETS

Administration route:

PER OS

Manufactured by:

MERCK SHARP & DOHME (ITALIA) S.P.A.

Therapeutic group:

SIMVASTATIN

Therapeutic indications:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH.Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Authorization date:

2012-04-01